公开(公告)号：US20240358639A1

公开(公告)日：2024-10-31

申请号：US18577129

申请日：2022-07-07

Applicant: Immix Biopharma, Inc.

Inventor： Ilya Rachman

IPC: A61K9/127 ,  A61K9/00 ,  A61K9/51 ,  A61K31/12 ,  A61K31/704 ,  A61K39/00 ,  A61P35/00 ,  B82Y5/00 ,  C07K16/28

CPC classification number: A61K9/1271 ,  A61K9/0019 ,  A61K9/5123 ,  A61K31/12 ,  A61K31/704 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505 ,  B82Y5/00

Abstract: The invention disclosed herein relates to nanoparticles containing one or more polykinase inhibitors and methods of using the same in combination with checkpoint inhibitors to treat cancer.

公开(公告)号：US20240335458A1

公开(公告)日：2024-10-10

申请号：US18681706

申请日：2022-08-05

Applicant: FOODVICA, S.A. DE C.V.

Inventor： Cynthia CANO-SARMIENTO ,  Ana Guadalupe CASTILLO-OLMOS ,  Hugo Sergio GARCÍA-GALINDO ,  Mizraim MORALES-MENDOZA

IPC: A61K31/575 ,  A61K31/12 ,  A61K36/9066 ,  A61P27/12

CPC classification number: A61K31/575 ,  A61K31/12 ,  A61K36/9066 ,  A61P27/12

Abstract: This invention provides an ophthalmic composition for the treatment and/or prevention of visual disorders caused by changes in the eye's lens structure, particularly related to the alteration of the proteins that form the lens. The ophthalmic composition consists of a polyphenolic compound in combination with a terpenoid, or its salts or crystalline forms, in therapeutically effective amounts, requiring low doses of bioactive compounds to treat the disease through a reduced number of applications. Specifically, the ophthalmic composition of the invention may be employed for the treatment and reversal of visual disorders caused by alterations in the structure of the crystalline lens, such as cataracts, by being able to reverse the opacity of the lens caused by the disease.

公开(公告)号：US12102686B2

公开(公告)日：2024-10-01

申请号：US16385854

申请日：2019-04-16

Applicant: University of Kentucky Research Foundation

Inventor： Thomas D. Dziubla ,  James Zach Hilt ,  Carolyn T. Jordan

IPC: A61K47/58 ,  A61K31/12 ,  A61K47/02 ,  A61K47/18 ,  A61K47/69

CPC classification number: A61K47/58 ,  A61K31/12 ,  A61K47/02 ,  A61K47/18 ,  A61K47/6927

Abstract: This invention concerns the incorporation of curcumin into the backbone of a hydrolytically degradable crosslinked hydrogel that utilizes poly(beta amino ester) (PBAE) chemistry to provide a tunable protective network with the ability to release at a controlled rate. Upon the introduction of these microparticle systems in to a free radical generating environment, the constituent amount of curcumin present in solution was improved in comparison to a free curcumin state. From these results, a kinetic rate model was developed to estimate oxidative consumption parameters of curcumin and curcumin monoacrylate and quantify theoretical levels of free radicals present depending on the rate of release of curcumin provided. Modeled curcumin conjugated PBAE microparticles improve translation and overall success in delivering a therapeutic agent that matches levels of oxidative stress.

公开(公告)号：US20240307320A1

公开(公告)日：2024-09-19

申请号：US18577088

申请日：2022-07-08

Applicant: Biophagy, Inc.

Inventor： Mary Ortner ,  Stuart Rose ,  Ian Henderson

IPC: A61K31/05 ,  A61B10/02 ,  A61K31/12 ,  A61K31/132 ,  A61K31/192 ,  A61K31/352 ,  A61K31/4412 ,  A61K31/7016

CPC classification number: A61K31/05 ,  A61B10/02 ,  A61K31/12 ,  A61K31/132 ,  A61K31/192 ,  A61K31/352 ,  A61K31/4412 ,  A61K31/7016 ,  A61B2010/0216

Abstract: A system for stimulating autophagy comprising a sample collection kit (either a buccal swab kit or a lancet kit) and one or more compounds that stimulate autophagy. The buccal swab kit has at least one buccal swab, a collection container, a storage device, a shipping package, a set of instructions, and at least one set of gloves. The lancet kit has at least one sterile lancet or an automated lancet device for capillary bloodletting, a sealed packet with an isopropyl alcohol wipe or pad, a collection container, a storage device, and a shipping package. A method of stimulating autophagy in an individual comprising the steps of providing the individual with at least one sample collection kit, testing the sample provided by the individual to determine the individual's level of autophagy, and administering one or more compounds to the individual to stimulate autophagy on a single use or subscription basis.

公开(公告)号：US12090122B2

公开(公告)日：2024-09-17

申请号：US17170956

申请日：2021-02-09

Applicant: Franco Cavaleri

Inventor： Franco Cavaleri

IPC: A61K36/00 ,  A61K9/48 ,  A61K31/12 ,  A61P3/06 ,  A61K36/9066

CPC classification number: A61K31/12 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61P3/06 ,  A61K36/9066 ,  A61K2300/00

Abstract: Methods and compositions for increasing LDL receptor levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 15% curcumin II or at least 5% curcumin III, in order to increase LDL receptor levels. In addition, compositions for increasing LDL receptor levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 15% curcumin II or at least 5% curcumin III (or combinations of such curcuminoids), along with a pharmaceutically-acceptable solvent, filler, or carrier. Still further, methods and compositions for decreasing MSK1 levels in a plurality of cells are disclosed, which involve administering a curcumin III-enriched composition to the cells.

公开(公告)号：US12059394B2

公开(公告)日：2024-08-13

申请号：US17266320

申请日：2019-08-05

Applicant: Givaudan France Naturals SAS

Inventor： Pascale Elizabeth Renée Fanca-Berthon ,  Leila Denise Falcao ,  Mathieu Tenon ,  Maryline Vinal ,  Simona Birtic

IPC: A61K31/12 ,  A61K36/185 ,  A61K47/36

CPC classification number: A61K31/12 ,  A61K36/185 ,  A61K47/36

Abstract: The present invention relates to methods and uses of compositions comprising curcumin; in particular, methods and uses relating to improving the bioaccessibility, bioavailability, bioefficacy and/or bioactivity of curcuminoids in mammals.

公开(公告)号：US12053439B2

公开(公告)日：2024-08-06

申请号：US17198102

申请日：2021-03-10

Applicant: California Northstate College of Pharmacy, LLC

Inventor： Indiran Pather ,  Tibebe Zewdie Woldemariam

IPC: A61K31/12 ,  A61K8/35 ,  A61K8/9789 ,  A61K8/9794 ,  A61K36/23 ,  A61Q17/04

CPC classification number: A61K31/12 ,  A61K8/35 ,  A61K8/9789 ,  A61K8/9794 ,  A61K36/23 ,  A61Q17/04 ,  A61K31/12 ,  A61K2300/00

Abstract: Methods of making safe extracts of Curcuma are provided. The processes provided include methods that use an extraction solvent that is at least substantially non-toxic and useful also as a pharmaceutically acceptable carrier in liquid dosage forms. The processes can produce a significantly higher yield from a single extraction than the state-of-the-art processes. For example, liquid dosage forms can be produced directly from the extraction process without requiring removal of the extraction solvent, reducing complexity and cost of processing over the state-of-the-art. Methods of making microemulsions and nanoemulsions are also provided to enhance the bioavailability and stability of the extracts.

公开(公告)号：US20240245607A1

公开(公告)日：2024-07-25

申请号：US18426838

申请日：2024-01-30

Applicant: Temple University-Of The Commonwealth System of Higher Education

Inventor： Gregory S. Smutzer ,  Kevin Lee ,  Dhruti Patel

IPC: A61K9/16 ,  A61K9/00 ,  A61K31/01 ,  A61K31/015 ,  A61K31/047 ,  A61K31/12 ,  A61K31/165 ,  A61K31/192 ,  A61K31/353 ,  A61K31/355 ,  A61K31/366 ,  A61K31/704 ,  A61K36/185 ,  A61K47/10 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61K47/46

CPC classification number: A61K9/1617 ,  A61K9/0056 ,  A61K9/1623 ,  A61K9/1682 ,  A61K31/01 ,  A61K31/015 ,  A61K31/047 ,  A61K31/12 ,  A61K31/165 ,  A61K31/192 ,  A61K31/353 ,  A61K31/355 ,  A61K31/366 ,  A61K31/704 ,  A61K36/185 ,  A61K47/10 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61K47/46

Abstract: The present invention relates to compositions and methods for masking the taste of an agent. In certain aspects, the invention comprises a microsphere and at least one sweetener therein. In another aspect, the invention comprises an edible material comprising at least one microsphere comprising an agent and at least one microsphere comprising a sweetener.

公开(公告)号：US12043594B2

公开(公告)日：2024-07-23

申请号：US17059762

申请日：2019-05-30

Applicant: EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION

Inventor： Kong Joo Lee ,  Hee-Yoon Lee ,  Je Jin Lee ,  Hongsoo Lee ,  Ji-wan Seo ,  Hwang Suk Kim ,  Bo-kyung Kim ,  Ji Soo Shin

IPC: C07C43/23 ,  A23L33/00 ,  A23L33/10 ,  A61K9/00 ,  A61K31/09 ,  A61K31/12 ,  A61K31/337 ,  A61P35/00 ,  C07C49/175

CPC classification number: C07C43/23 ,  A23L33/10 ,  A23L33/40 ,  A61K9/0056 ,  A61K31/09 ,  A61K31/12 ,  A61K31/337 ,  A61P35/00 ,  C07C49/175 ,  A23V2002/00

Abstract: The present disclosure provides a novel biphenyl derivative compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof. The biphenyl derivative compound, optical isomer thereof or pharmaceutically acceptable salt thereof according to the present disclosure may induce cancer cell death by damaging mitochondria and inducing ATP depletion in cells which are in a nutrient-starved state such as a glucose-starved state, which is the normal environment of cancer cells. In addition, it is an Nm23-H1/NDPK activity-increasing substance that may suppress cancer metastasis and growth. Thus, it exhibits excellent effects not only on the prevention, alleviation and treatment of cancer, but also on the suppression of cancer metastasis.

公开(公告)号：US20240226027A1

公开(公告)日：2024-07-11

申请号：US18409244

申请日：2024-01-10

Applicant: Nuecology Biomedical Inc.

Inventor： Chung Chin SUN ,  Dean Mo LIU

IPC: A61K9/51 ,  A61K9/00 ,  A61K31/07 ,  A61K31/12 ,  A61K31/337 ,  A61K31/355 ,  A61K31/4745 ,  A61K31/704 ,  A61P35/00 ,  C07K16/32

CPC classification number: A61K9/5161 ,  A61K9/0019 ,  A61K31/07 ,  A61K31/12 ,  A61K31/337 ,  A61K31/355 ,  A61K31/4745 ,  A61K31/704 ,  A61P35/00 ,  C07K16/32

Abstract: This invention discloses an injectable nanocomposite gel composition and the method of making the composition. The composition is composed of amphiphilic alginate nanoparticle, gel stabilizer, gel crosslinker, and gel structural modifiers. The nanocomposite gel can be manufactured into a form of highly-viscous gel or a solid-like gel, used as a vehicle to carry and deliver pharmaceutically active ingredients with high drug load via injection administration for medical uses.